Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S V Gulnik

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
AIDS (London, England)|July 8, 2000
Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapiesJ W Erickson, S V Gulnik, M Markowitz
Nature Structural Biology|October 23, 1998
Conformational switching in an aspartic proteinaseA Y Lee, S V Gulnik, J W Erickson
Advances in Experimental Medicine and Biology|January 1, 1991
Human stomach cathepsin E action on human immunoglobulinsA F Kisseljov, S V Gulnik, N I Tarasova
Protein Science : a Publication of the Protein Society|July 1, 1997
Structure-based subsite specificity mapping of human cathepsin D using statine-based inhibitorsP Majer, J R Collins, S V Gulnik, et al.
Biochemistry|July 25, 1995
Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressureS V Gulnik, L I Suvorov, B Liu, et al.
Advances in Experimental Medicine and Biology|January 1, 1991
A new type of aspartic proteinase inhibitors with a symmetric structureN I Tarasova, S V Gulnik, A A Prischenko, et al.
Advances in Experimental Medicine and Biology|April 30, 1998
Sensitivity to inhibition and catalytic efficiency of HIV proteinase mutantsS I Wilson, L H Phylip, S V Gulnik, et al.
FEBS Letters|August 18, 1997
Design of sensitive fluorogenic substrates for human cathepsin DS V Gulnik, L I Suvorov, P Majer, et al.
Biochimica Et Biophysica Acta|April 25, 1997
Escape mutants of HIV-1 proteinase: enzymic efficiency and susceptibility to inhibitionS I Wilson, L H Phylip, J S Mills, et al.
Bioorganic & Medicinal Chemistry|September 1, 1996
Structure-based design of achiral, nonpeptidic hydroxybenzamide as a novel P2/P2' replacement for the symmetry-based HIV protease inhibitorsR S Randad, L Lubkowska, A M Silva, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
AIDS (London, England)|July 8, 2000
Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapiesJ W Erickson, S V Gulnik, M Markowitz
Nature Structural Biology|October 23, 1998
Conformational switching in an aspartic proteinaseA Y Lee, S V Gulnik, J W Erickson
Advances in Experimental Medicine and Biology|January 1, 1991
Human stomach cathepsin E action on human immunoglobulinsA F Kisseljov, S V Gulnik, N I Tarasova
Protein Science : a Publication of the Protein Society|July 1, 1997
Structure-based subsite specificity mapping of human cathepsin D using statine-based inhibitorsP Majer, J R Collins, S V Gulnik, et al.
Biochemistry|July 25, 1995
Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressureS V Gulnik, L I Suvorov, B Liu, et al.
Advances in Experimental Medicine and Biology|January 1, 1991
A new type of aspartic proteinase inhibitors with a symmetric structureN I Tarasova, S V Gulnik, A A Prischenko, et al.
Advances in Experimental Medicine and Biology|April 30, 1998
Sensitivity to inhibition and catalytic efficiency of HIV proteinase mutantsS I Wilson, L H Phylip, S V Gulnik, et al.
FEBS Letters|August 18, 1997
Design of sensitive fluorogenic substrates for human cathepsin DS V Gulnik, L I Suvorov, P Majer, et al.
Biochimica Et Biophysica Acta|April 25, 1997
Escape mutants of HIV-1 proteinase: enzymic efficiency and susceptibility to inhibitionS I Wilson, L H Phylip, J S Mills, et al.
Bioorganic & Medicinal Chemistry|September 1, 1996
Structure-based design of achiral, nonpeptidic hydroxybenzamide as a novel P2/P2' replacement for the symmetry-based HIV protease inhibitorsR S Randad, L Lubkowska, A M Silva, et al.
Pageof 2